Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
PositiveHealth
- Merck is currently in discussions to acquire Revolution Medicines, a biotechnology company focused on developing cancer-targeting drugs, in a potential deal valued at approximately $30 billion. This acquisition could significantly enhance Merck's portfolio in the oncology sector.
- The acquisition of Revolution Medicines would not only bolster Merck's capabilities in cancer treatment but also position the company as a leader in innovative therapies, reflecting a strategic move to expand its influence in the competitive biotech landscape.
— via World Pulse Now AI Editorial System